Quote | Greenwich LifeSciences Inc. (NASDAQ:GLSI)
Last: | $16.71 |
---|---|
Change Percent: | -0.72% |
Open: | $16.82 |
Close: | $16.71 |
High: | $16.98 |
Low: | $16.07 |
Volume: | 35,496 |
Last Trade Date Time: | 07/05/2024 03:00:00 am |
News | Greenwich LifeSciences Inc. (NASDAQ:GLSI)
2024-06-26 14:05:02 ET Summary Greenwich LifeSciences, Inc. approaches enrollment completion for the phase 3 Flamingo-01 study, using GLSI-100 for the treatment of patients with HER2/neu positive breast cancer, with full enrollment expected by the end of 2024. A prior phase 2b stu...
2024-06-26 13:45:17 ET Summary Greenwich LifeSciences, Inc. is a late-stage biotech company focusing on developing an immunotherapy treatment for breast cancer. Their pipeline includes one drug, GLSI-100, currently in a phase 3 trial targeting breast cancer recurrence after surger...
Message Board Posts | Greenwich LifeSciences Inc. (NASDAQ:GLSI)
Subject | By | Source | When |
---|---|---|---|
AviseAnalytics: HERES WHY YOU SHOULD KEENLY WATCH GREENWICH LIFESCIENCES $GLSI Greenwich LifeSc | AviseAnalytics | investorshangout | 07/14/2022 12:04:23 PM |
I like how greenwhich is raising money in | McMagyar | investorshub | 07/13/2022 2:44:31 PM |
znewcar1: GLSI 38% v8,9M c11.98 f13M H14.29 gap rocket S10.4 ML6.82 | znewcar1 | investorshangout | 07/13/2022 2:40:23 AM |
Amazing how that pump and dump worked. What | NYCPuglet | investorshub | 08/12/2021 8:10:15 PM |
New to $GLSI. WTF happened last night/ | DiviningRod | investorshub | 04/12/2021 4:12:34 PM |
News, Short Squeeze, Breakout and More Instantly...
Greenwich LifeSciences Inc. Company Name:
GLSI Stock Symbol:
NASDAQ Market:
Greenwich LifeSciences Inc. Website:
STAFFORD, Texas, June 26, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, tod...
STAFFORD, Texas, June 14, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company" or "Greenwich"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer r...
2024-05-11 10:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...